A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer (NCT07505771)

🧪 Interventions in This Study

• 177Lu-IM-3050 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (3 Sites)

• Stanford University School of Medicine — Palo Alto, California
• University of Texas - MD Anderson Cancer Center — Houston, Texas
• Excel Diagnostics and Nuclear Oncology Center — Houston, Texas

📞 Contact the Study Coordinator

Phone: (425) 939-7410

Email: info@immunome.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Malignancies

• Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens — Calgary, Alberta
• A Phase 1 Study of IM-1021 in Participants With Advanced Cancer — Duarte, California
• A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies — Dallas, Texas

Explore by condition: All Solid Malignancies clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.